ICIs for HCC: Overview

CME

An Expert Overview of Immunotherapy for Advanced HCC

Physicians: Maximum of 0.25 AMA PRA Category 1 Credit

Released: January 19, 2021

Expiration: January 18, 2022

Lipika Goyal
Lipika Goyal, MD, MPhil
Amit G. Singal
Amit G. Singal, MD, MS

Activity

Progress
1
Course Completed

In this episode, Amit G. Singal, MD, MS, and Lipika Goyal, MD, discuss key considerations in the contemporary use of immune checkpoint inhibitors for treating patients with advanced hepatocellular carcinoma, with topics including:

  • Optimal use of the newly approved immune checkpoint inhibitor/VEGF inhibitor combination of atezolizumab plus bevacizumab
  • Use of nivolumab ± ipilimumab and pembrolizumab
  • Emerging immunotherapy combinations currently being investigated in clinical trials
  • Management of key adverse events with immune checkpoint inhibitors